GSK
GSK
919 hedge funds and large institutions have $14.5B invested in GSK in 2021 Q4 according to their latest regulatory filings, with 192 funds opening new positions, 321 increasing their positions, 247 reducing their positions, and 52 closing their positions.
269% more first-time investments, than exits
New positions opened: 192 | Existing positions closed: 52
168% more call options, than puts
Call options by funds: $624M | Put options by funds: $233M
46% more funds holding in top 10
Funds holding in top 10: 13 → 19 (+6)
30% more repeat investments, than reductions
Existing positions increased: 321 | Existing positions reduced: 247
17% more capital invested
Capital invested by funds: $12.4B → $14.5B (+$2.08B)
16% more funds holding
Funds holding: 793 → 919 (+126)
0.07% more ownership
Funds ownership: 5.14% → 5.21% (+0.07%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
+$175M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$147M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$61.6M |
| 4 |
Goldman Sachs
New York
|
+$56.8M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$253M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$147M |
| 3 |
Two Sigma Advisers
New York
|
-$101M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$88.8M |
| 5 |
Two Sigma Investments
New York
|
-$63.9M |
GSK Hedge Fund Activity: Q4 2021 in Review
919 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2021, worth a combined $14.5B — up 17% from $12.4B a quarter earlier.
Buyers outnumbered sellers: 192 funds opened new GSK positions and 52 closed out — a net gain of 140 holders — while 321 added to existing stakes and 247 trimmed.
The largest buyer was Nomura Holdings, adding an estimated $175M. The largest seller was UBS Group, cutting an estimated $253M.
- 919 institutional investors held GSK (GSK) as of Q4 2021, up from 793 in Q3 2021.
- Funds reported $14.5B of GSK stock for Q4 2021, up 17% quarter-over-quarter.
- 192 funds opened new GSK positions in Q4 2021 and 52 closed out, a net change of +140 holders.
- The largest GSK buyer in Q4 2021 was Nomura Holdings, an estimated $175M added.
- The largest GSK seller in Q4 2021 was UBS Group, an estimated $253M sold.
Based on aggregated 13F filings for Q4 2021.